AVIR
Atea Pharmaceuticals, Inc.
There isn't enough reported data to score AVIR yet.
AVIR Fundamentals
| Metric | Status |
|---|---|
| Unavailable | |
| Stable | |
| Unavailable | |
| Healthy |
AVIR's balance sheet is currently healthy, and its profitability is stable. There isn't enough data to rate its revenue and cash flow.
AVIR PE Valuation
AVIR has no meaningful PE right now: it lost money over the past year.
AVIR Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Strong decline | |
| -- | |
| Limited | |
| Low |
Analysts expect AVIR's losses to shrink, with revenue declining. However, they disagree widely on these estimates.
AVIR Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$1.95 | -$0.18 |
| Q2 2026 | -$2.08 | -$0.47 |
| Q1 2026 | -$2.11 | -$0.46 |
| Q4 2025 | -$1.94 | +$0.06 |
| Q3 2025 | -$1.77 | +$0.29 |
| Q2 2025 | -$1.61 | +$0.48 |
| Q1 2025 | -$1.65 | +$0.30 |
| Q4 2024 | -$2.00 | -$0.37 |
AVIR lost $1.95 per share over the past year, a bigger loss than the year before.
AVIR Quarterly Revenue
| Quarter | Margin | YoY |
|---|---|---|
| Q4 2021 | 63% | N/A |
| Q3 2021 | -68% | N/A |
| Q2 2021 | 14% | N/A |
| Q1 2021 | 46% | N/A |
AVIR Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$28.9M | +$11.5M |
| Q2 2026 | -$37.1M | -$4.2M |
| Q1 2026 | -$46.4M | -$15.8M |
| Q4 2025 | -$28.2M | +$2.2M |
| Q3 2025 | -$40.4M | -$17.3M |
| Q2 2025 | -$32.9M | +$9.3M |
| Q1 2025 | -$30.6M | +$9.3M |
| Q1 2022 | -$59.1M | -$42.2M |
AVIR has burned cash in almost every quarter: −$141M over the past year, against −$134M the year before.
AVIR Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.2% | +174K shares |
| 1 year | +1.5% | +1.2M shares |
| 3 years | -3.8% | -3.2M shares |
| 5 years | -3.1% | -2.6M shares |
| Available history | +70% | +32.9M shares |
AVIR has 80M diluted shares, up 1.5% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2025 | — |
| Q3 2025 | $11.4M |
| Q2 2020 | — |
| Q1 2020 | — |
| Q4 2019 | — |
AVIR Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2022 | -5.8x | Net Cash |
| Q2 2022 | -27.8x | Net Cash |
| Q1 2022 | -10.8x | Net Cash |
| Q4 2021 | -5.5x | Net Cash |
| Q3 2021 | -22.2x | Net Cash |
| Q2 2021 | -19.3x | Net Cash |
| Q1 2021 | -35.2x | Net Cash |
AVIR has more cash than debt.
AVIR Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 41.5 | Neutral |
| Stochastic | 15.8 | Oversold |
AVIR's weekly RSI is 41 (neutral) and its Stochastic is 16 (oversold).
AVIR PE vs Healthcare Sector
| Metric | AVIR | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
AVIR has no meaningful PE right now: it lost money over the past year.
AVIR Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $4.56 | 7.7% below |
| 20 week MA | $4.92 | 14% below |
| 50 week MA | $4.70 | 10% below |
| 100 week MA | $3.93 | 7.1% above |
| 200 week MA | $3.76 | 12% above |
AVIR has pulled back, but its long-term trend is still up: it's below its 8-, 20- and 50-week averages, but 12% above its 200-week average.
AVIR Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $30.3 | $34.5 | +14% |
| 2021 | $34.5 | $9.11 | -74% |
| 2022 | $9.11 | $4.59 | -50% |
| 2023 | $4.59 | $3.05 | -34% |
| 2024 | $3.05 | $3.33 | +9.2% |
| 2025 | $3.33 | $3.65 | +9.6% |
| 2026 YTD | $3.65 | $4.21 | +15% |
AVIR has finished lower in three of the last six years. It's up 15% so far in 2026.